MiNA Therapeutics
RNA Activation – MiNA Therapeutics | RNA Activation
London, United Kingdom · Founded 2008 · $175.0M raised
- Headquarters
- London
- Employees
- 11–50
- Founded
- 2008
- Business Model
- B2B
- Website
- minatx.com
- Total Funding
- $175.0M
- Last Round
- $130.0M Series CJan 2023
- Rounds
- 3
About
MiNA Therapeutics is the global leader in small activating RNA (RNAa) therapeutics, harnessing innate mechanisms of gene activation to restore or boost normal gene function. The company advances a proprietary pipeline focused on genetic medicine while collaborating with leading pharmaceutical companies including Eli Lilly to apply its RNAa platform across a broad range of therapeutic areas.
Summary
MiNA Therapeutics is a Biotech company based in London, United Kingdom, founded in 2008. It has raised $175.0M in total across 3 rounds, most recently a $130.0M Series C round in Jan 2023. Investors include Eli Lilly and aMoon.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2023
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...